Citations

Clear

439 citation(s) found for "Stone, M".

Neurologists Unite for Ukraine: Grassroots Movement Transformed into Lasting Collaboration (P4-8.013)
BriscoeAbath, Christina, Tychkivska, Olha, Minster, Anna, Anselm, Irina , Sharinn, Alina, Paciorkowski, Alexander, Snyder, Yuliya, Corcoran, Mike , Stone, Todd, Samad, Ozzy, Kielian, Agnieszka, Faktorovich, Svetlana, Hadjinicolaou, Aristides , Friedman, Danielle, Ivaniuk, Alina , Wirrell, Elaine , Corcoran, Mike

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000204162 Get It

Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials
Bhatt, Vijaya Raj , Ulrich, Angela M. , Uy, Geoffrey L. , Stone, Richard M. , Stock, Wendy , Ojelabi, Michael Olayiwola , Yin, Jun , Kohlschmidt, Jessica, Eisfeld, Ann‐Kathrin , Baer, Maria R. , Chow, Selina , Jatoi, Aminah , Ojelabi, Michael O , Klepin, Heidi D , Le-Rademacher, Jennifer G , Stock, Wendy , Bhatt, Vijaya Raj , Uy, Geoffrey , Klepin, Heidi D. , Le‐Rademacher, Jennifer

Mayo Clinic

JCO Oncology Practice | April 14, 2023 | Volume: 19 | Issue: 6 | Pages: e877-e891

10.1200/op.22.00822 | PMID 37058684 Get It

PURPOSE: Clinical trials are important for managing older patients with AML. We investigated differences in outcomes of older patients with AML on the basis of whether patients participated in intensive chemotherapy trials at community versus academic cancer centers. METHODS: We used data from the Alliance for Clinical Trials in Oncology phase III trials that enrolled patients age ≥ 60 years with newly diagnosed AML between 1998 and 2002 in the Cancer and Leukemia Group B (CALGB) 9720 trial and between 2004 and 2006 in the CALGB 10201 trial. Centers funded by the NCI Community Oncology Research Program were identified as community cancer centers; others were designated as academic cancer centers. Logistic regression models and Cox proportional hazards models were used to compare 1-month mortality and overall survival (OS) by center type. RESULTS: Seventeen percent of the 1,170 patients were enrolled in clinical trials in community cancer centers. The study results demonstrated comparable rates of grade ≥3 adverse events (97% v 93%), 1-month mortality (19.1% v 16.1%), and OS (43.9% v 35.7% at 1 year) between community versus academic cancer centers, respectively. After adjusting for covariates, 1-month mortality (odds ratio, 1.40; 95% CI, 0.92 to 2.12; P = .11) and OS (hazard ratio, 1.04; 95% CI, 0.88 to 1.22; P = .67) were not statistically different among patients treated in community versus academic cancer centers. CONCLUSION: An older patient population, who have complex health care needs, can be successfully treated on intensive chemotherapy trials in select community cancer centers with outcomes comparable with that achieved at academic cancer centers.
The Role of Shear Stress in Coronary Artery Disease
Siasos, Gerasimos , Tsigkou, Vasiliki , Coskun, Ahmet U. , Zaromitidou, Marina , Lerman, Lilach O. , Stone, Peter H. , Oikonomou, Evangelos , Lerman, Amir

Mayo Clinic

Current Topics in Medicinal Chemistry | March 30, 2023 | Volume: 23 | Issue: 22 | Pages: 2132-2157

10.2174/1568026623666230329085631 | PMID 36999430 Get It

Abstract:Coronary artery disease is the leading cause of morbidity and mortality worldwide, espe-cially in developed countries, with an increasing incidence in developing countries. Despite the ad-vances in cardiology, there are yet many unanswered questions about the natural history of coronary atherosclerosis. However, it has not been fully explained why some coronary artery plaques remain quiescent over time, whereas others evolve to a high-risk, “vulnerable” plaque with a predisposition to destabilize and induce a cardiac event. Furthermore, approximately half of the patients with acute coronary syndromes demonstrate no prior symptoms of ischemia or angiographically evident dis-ease. Recent findings have indicated that apart from cardiovascular risk factors, genetics, and other unknown factors, local hemodynamic forces, such as endothelial shear stress, blood flow patterns, and endothelial dysfunction of the epicardial and microvascular coronary arteries, are associated with the progression of coronary plaque and the development of cardiovascular complications with complex interactions. In this review article, we summarize the mechanisms that affect coronary ar-tery plaque progression, indicating the importance of endothelial shear stress, endothelial dysfunc-tion of epicardial and microvascular vessels, inflammation, and their complex associations, underly-ing in parallel the clinical perspectives of these findings.
Characterization of Stone Events in Patients With Type 3 Primary Hyperoxaluria
Arnous, Muhammad G. , Vaughan, Lisa E. , Mehta, Ramila A. , Schulte, Phillip J. , Lieske, John C. , Milliner, Dawn S. , Vaughan, Lisa, Lieske, John C

Mayo Clinic

Journal of Urology | March 8, 2023 | Volume: 209 | Issue: 6 | Pages: 1141-1150

10.1097/ju.0000000000003400 | PMID 36888927 Get It

Two‐Year Outcomes With a Next‐Generation Left Atrial Appendage Device: Final Results of the PINNACLE FLX Trial
Doshi, Shephal K. , Kar, Saibal , Sadhu, Ashish, Horton, Rodney , Osorio, José , Ellis, Christopher R. , Stone, James, Shah, Manish H. , Dukkipati, Srinivas R. , Adler, Stuart W., Kim, Jamie , Wazni, Oussama M. , Holmes, David R. , Shipley, Robert D., Christen, Thomas, Allocco, Dominic J. , Buchbinder, Maurice , Chinitz, Larry A. , Desai, Amish J., Dukkipatti, Srinivas R., Ellis, Christopher, Gibson, Douglas , Huber, Kenneth, Khairallah, Farhat, Koneru, Jayanthi N. , Mahoney, Paul G. , Mansour, Moussa , Mark, George E., Nicholson, William , REISS, J. A., Shehata, Michael , Swarup, Vijendra, Huber, Kurt , Téllez-Plaza, María , Ellis, Christopher , Shah, Manish , Nair, Devi G , Wazni, Oussama , Price, Matthew J , Holmes, David R , Reddy, Vivek Y , Kar, Saibal , Huber, Kurt , Price, Matthew J. , Reddy, Vivek Y. , DeLurgio, David B. , Ellis, Christopher, Huber, Kenneth, Mahoney, Paul, O’Neill, William W. , Reiss, James, Saliba, Walid I.

Mayo Clinic

Journal of the American Heart Association | February 21, 2023 | Volume: 12 | Issue: 4 | Pages: No page available

10.1161/jaha.122.026295 | PMID 36789852 Get It

Background The PINNACLE FLX (Protection Against Embolism for Non‐valvular AF [Atrial Fibrillation] Patients: Investigational Device Evaluation of the Watchman FLX LAA [Left Atrial Appendage] Closure Technology) trial evaluated the safety and efficacy of a next‐generation left atrial appendage closure device (WATCHMAN FLX; Boston Scientific, Marlborough, MA). At 1 year, the study met the primary end points of safety and anatomical efficacy/appendage closure. This final report of the PINNACLE FLX trial includes the prespecified secondary end point of ischemic stroke or systemic embolism at 2 years, also making it the first report of 2‐year outcomes with this next‐generation left atrial appendage closure device. Methods and Results Patients with nonvalvular atrial fibrillation with CHA 2 DS 2 ‐VASc score ≥2 (men) or ≥3 (women), with an appropriate rationale for left atrial appendage closure, were enrolled to receive the left atrial appendage closure device at 29 US centers. Adverse events were assessed by an independent clinical events committee, and imaging was assessed by independent core laboratories. Among 395 implanted patients (36% women; mean age, 74 years; CHA 2 DS 2 ‐VASc, 4.2±1.5), the secondary efficacy end point of 2‐year ischemic stroke or systemic embolism was met, with an absolute rate of 3.4% (annualized rate, 1.7%) and an upper 1‐sided 95% confidence bound of 5.3%, which was superior to the 8.7% performance goal. Two‐year rates of adverse events were as follows: 9.3% all‐cause mortality, 5.5% cardiovascular death, 3.4% all stroke, and 10.1% major bleeding (Bleeding Academic Research Consortium 3 or 5). There were no additional systemic embolisms, device embolizations, pericardial effusions, or symptomatic device‐related thrombi after 1 year. Conclusions The secondary end point of 2‐year stroke or systemic embolism was met at 3.4%. In these final results of the PINNACLE FLX trial, the next‐generation WATCHMAN FLX device demonstrated favorable safety and efficacy outcomes.
Left-sided valvular heart disease and retinopathy in a 38-year-old woman with attenuated mucopolysaccharidosis: a case report
Asumda, Faizal Z., Kraker, Jessica A. , Thomas, Sarah , Maleszewski, Joseph J. , Stone, Edwin M. , Lanpher, Brendan C. , Schimmenti, Lisa A. , Thomas, Sarah C, Maleszewski, Joseph, Schimmenti, Lisa A , Thomas, Sarah C.

Mayo Clinic

Therapeutic Advances in Rare Disease | January 13, 2023 | Volume: 4 | Issue: No issue available | Pages: No page available

10.1177/26330040221145945 | PMID 37181073 Get It

Mucopolysaccharidoses (MPS) are a group of inherited lysosomal storage disorders caused by deficient levels and/or activity of glycosaminoglycan (GAG)-degradative enzymes. MPS are characterized by accumulation of the mucopolysaccharides heparan sulfate, dermatan sulfate, keratan sulfate, or chondroitin sulfate in tissues. We report the case of a 38-year-old woman with a history of joint restriction and retinitis pigmentosa who developed bivalvular heart failure requiring surgery. It was not until pathological examination of surgically excised valvular tissue that a diagnosis of MPS I was made. Her musculoskeletal and ophthalmologic symptoms, when placed in the context of MPS I, painted the diagnostic picture of a genetic syndrome that was overlooked until a diagnosis was made in late middle age.
Detection of Cadmium and Lead in Kidney Stones. Associations with Patient Demographics, Stone Composition, and Smoking
Day, Patrick L. , Wermers, Michelle, Jannetto, Paul J. , Bornhorst, Joshua A. , Pazdernik, Vanessa , Bornhorst, Joshua , Day, Patrick

Mayo Clinic

The Journal of Applied Laboratory Medicine | December 28, 2022 | Volume: 8 | Issue: 2 | Pages: 330-340

10.1093/jalm/jfac089 | PMID 36575923 Get It

Abstract Background Kidney stones are a highly prevalent disease worldwide. Additionally, both environmental and occupational exposure to Pb and Cd continue to be prevalent globally and can result in renal toxicity. The objective of this study was to examine the potential presence of Pb and Cd in kidney stones, and to assess for correlation with demographic factors including smoking, gender, age, and kidney stone matrix composition. Methods Patient kidney stones (n = 96) were analyzed using Fourier transform infrared spectroscopy to identify the stone constituents. Cd and Pb concentrations (µg/g) were determined by inductively coupled plasma mass spectrometry. Cd and Pb concentrations were correlated using bivariable and multivariable statistical analysis with demographic factors (age, gender, smoking status), and kidney stone composition. Results Kidney stone Cd (median 0.092 µg/g, range 0.014 to 2.46) and Pb concentrations (median 0.95 µg/g, range 0.060 to 15.4) were moderately correlated (r = 0.56, P < 0.0001). Cd concentrations were positively associated with patient history of smoking, patient age, and calcium oxalate monohydrate levels while negatively associated with struvite and uric acid/uric acid dihydrate. Pb concentrations were positively associated with females and apatite levels while negatively associated with uric acid/uric acid dihydrate. After holding constant other stone type composition levels, smoking status, and age, both Pb and Cd were positively associated with apatite and negatively associated with uric acid/uric acid dihydrate, struvite, and calcium carbonate. Conclusions Cd and Pb kidney stone concentrations are associated with specific kidney stone types. Cd and Pb kidney stone concentrations are both associated with smoking.
Activation of a Latent Epitope Causing Differential Binding of Antineutrophil Cytoplasmic Antibodies to Proteinase 3
Moura, Marta Casal , Thompson, Gwen , Nelson, Darlene R. , Fussner, Lynn A. , Hummel, Amber M., Jenne, Dieter E. , Emerling, Daniel , Kallenberg, Cees G. M., Langford, Carol A. , McCune, W. Joseph, Clair, E. William St. , Ytterberg, Steven R. , Stone, John H. , Robinson, William H. , Casal Moura, Marta , Thompson, Gwen E, Merkel, Peter A , Monach, Paul A , Spiera, Robert F , Stone, John H , Robinson, William H , Fervenza, Fernando C. , Merkel, Peter A. , Monach, Paul A. , Seo, Philip , Spiera, Robert , Specks, Ulrich

Mayo Clinic

Arthritis & Rheumatology | December 14, 2022 | Volume: 75 | Issue: 5 | Pages: 748-759

10.1002/art.42418 | PMID 36515151 Get It

Objective Proteinase 3 (PR3) is the major antigen for antineutrophil cytoplasmic antibodies (ANCAs) in the systemic autoimmune vasculitis, granulomatosis with polyangiitis (GPA). PR3‐targeting ANCAs (PR3‐ANCAs) recognize different epitopes on PR3. This study was undertaken to study the effect of mutations on PR3 antigenicity. Methods The recombinant PR3 variants, iPR3 (clinically used to detect PR3‐ANCAs) and iHm5 (containing 3 point mutations in epitopes 1 and 5 generated for epitope mapping studies) immunoassays and serum samples from patients enrolled in ANCA‐associated vasculitis (AAV) trials were used to screen for differential PR3‐ANCA binding. A patient‐derived monoclonal ANCA 518 (moANCA518) that selectively binds to iHm5 within the mutation‐free epitope 3 and is distant from the point mutations of iHm5 was used as a gauge for remote epitope activation. Selective binding was determined using inhibition experiments. Results Rather than reduced binding of PR3‐ANCAs to iHm5, we found substantially increased binding of the majority of PR3‐ANCAs to iHm5 compared to iPR3. This differential binding of PR3‐ANCA to iHm5 is similar to the selective moANCA518 binding to iHm5. Binding of iPR3 to monoclonal antibody MCPR3‐2 also induced recognition by moANCA518. Conclusion The preferential binding of PR3‐ANCAs from patients, such as the selective binding of moANCA518 to iHm5, is conferred by increased antigenicity of epitope 3 on iHm5. This can also be induced on iPR3 when captured by monoclonal antibody MCPR2. This previously unrecognized characteristic of PR3‐ANCA interactions with its target antigen has implications for studying antibody‐mediated autoimmune diseases, understanding variable performance characteristics of immunoassays, and design of potential novel treatment approaches. image
Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age
Winer, Eric S. , Shallis, Rory M. , Stahl, Maximilian , Oh, Timothy S. , Ma, Karen , Litzow, Mark R. , Bradshaw, Danielle , Stone, Richard M. , Flamand, Yael , Stempel, Jessica M. , Goldberg, Aaron D. , Patel, Anand , DuVall, Adam , Abaza, Yasmin , Ma, Karen, Badar, Talha , Kota, Vamsi , Raman, Hari S. , Luskin, Marlise R , DeAngelo, Daniel J.

Mayo Clinic

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6285-6287

10.1182/blood-2022-170587 Get It

Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience
Issa, Ghayas C., Cuglievan, Branko , Stein, Eytan M. , Arellano, Martha , Khera, Nandita , Stone, Richard M. , Thirman, Michael J. , Karras, Nicole, Gu, Yu , Bagley, Rebecca G., Rosen, Galit, Tamang, David, Dishman, Kimberly, Scalera, Sushama, Meyers, Michael L., Madigan, Kate, McNeer, Nicole, Issa, Ghayas , Žučenka, Andrius , DiPersio, John F. , Madigan, Kate, Aldoss, Ibrahim

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 914-916

10.1182/blood-2022-164600 Get It